A novel predictive factor for the onset time of docetaxel-induced onychopathy: a multicenter retrospective study

A novel predictive factor for the onset time of docetaxel-induced onychopathy: a multicenter retrospective study

Journal of Pharmaceutical Health Care and Sciences, September 2016

27708837

Hidenobu Takahata, Kouichi Tanabe, Akiyoshi Takaki, Tsuneaki Yamanouchi, Yasuhiko Mimura, Atsumi Nitta, Hatsuna Yasuda, Tatsuhiko Kashii, Isao Adachi

Taxanes are known to cause onychopathy. Previous studies have reported the relationship between onychopathy and paclitaxel dosing intervals and cumulative doses. However, there are no studies of the predictive factors for docetaxel-induced nail changes. The present study used the drug accumulation rate (mg/m(2)/day) as a novel indicator and evaluated its usefulness for the prediction of onychopathy. From January 2008 to December 2009, we examined patients who received docetaxel at the Toyama University Hospital and Tonami General Hospital to determine the time to onset of onychopathy, the accumulation rate, and the cumulative dose. We then divided the study subjects into two groups, and used Receiver Operating Characteristic (ROC) analysis to calculate a cut-off value. We evaluated both indicators as predictive factors for onychopathy using the log-rank test and Cox proportional hazards model. Ninety-five patients were included in the present study. The results of the log-rank test sub-analysis revealed that the median number of days until onychopathy onset was significantly shorter in patients with an accumulation rate greater than the cut-off (P = 0.009), and in those with a cumulative dose below the cut-off (P < 0.001). The hazard ratios for the accumulation rate and cumulative dose, evaluated using Cox proportional hazards regression analysis, were 1.44 (P = 0.036) and 0.99 (P < 0.001), respectively. The results of the present study indicated that the drug accumulation rate influenced the time to onset of docetaxel-induced onychopathy. This study is not applicable for trial registration due to retrospective chart review without intervention.